【标题速读】【Nm】【2022年】【7-12月】
声明：本专栏主要对生命科学领域的一些期刊文章标题进行翻译，所有内容均由本人手工整理翻译。由于本人专业为生物分析相关，其他领域如果出现翻译错误请谅解。
Two papers by Saria and colleagues in this issue report results from the prospective evaluation of deployment of a machine learning–based early warning system for sepsis in five hospitals. The cover depicts elements of the integrated artificial intelligence platform that expands the capacity of healthcare providers to visualize and interpret signs of deterioration associated with sepsis, leading to opportunities for early intervention and improved patient outcomes.
Saria及其同事在本期中发表的两篇论文报告了对五家医院部署基于机器学习的败血症早期预警系统的前瞻性评估结果。封面描述了集成人工智能平台的元素，该平台扩展了医疗保健提供者可视化和解释与败血症相关的恶化迹象的能力，从而为早期干预和改善患者预后提供了机会。
1.Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Onasemnogene abeparvovec治疗有两个SMN2拷贝的无症状婴儿，有患脊髓性肌肉萎缩症1型的风险：III期SPR1NT试验。
2.Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Onasemnogene abeparvovec治疗有三个SMN2拷贝的无症状婴儿，有脊柱肌萎缩的风险：III期SPR1NT试验。
3.Performance of plasma phosphorylated tau 181 and 217 in the community.
社区中血浆磷酸化tau181和217的表现。
4.Parental inflammatory bowel disease and autism in children.
父母的炎症性肠病和儿童自闭症。
5.Genome-wide polygenic score to predict chronic kidney disease across ancestries.
全基因组多基因评分预测跨血统的慢性肾脏病。
6.A T cell resilience model associated with response to immunotherapy in multiple tumor types.
一种与多种肿瘤类型的免疫疗法反应有关的T细胞复原力模型。
7.Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
利格列净治疗非酒精性脂肪性肝炎：一项随机、双盲、安慰剂对照的2a期研究。
8.Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects.
克隆造血的纵向动力学确定了基因特定的健身效果。
9.Factors driving provider adoption of the TREWS machine learning-based early warning system and its effects on sepsis treatment timing.
推动供应商采用基于机器学习的TREWS预警系统的因素及其对败血症治疗时机的影响。
10.Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis.
基于TREWS机器学习的败血症早期预警系统实施后的患者结果的前瞻性、多站点研究。
11.Long COVID after breakthrough SARS-CoV-2 infection.
突破性SARS-CoV-2感染后的长COVID。
12.Modeling transmission of SARS-CoV-2 Omicron in China.
中国SARS-CoV-2 Omicron的传播模型。
13.Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals.
巴西医院中COVID-19死亡率的空间和时间上的波动。
14.Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
第二次BNT162b2强化疫苗对60岁以上成人COVID-19住院和死亡的有效性。
15.Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
未接种疫苗和接种疫苗的人感染祖传的、Delta或Omicron SARS-CoV-2的传染性病毒量。
16.Drivers of adaptive evolution during chronic SARS-CoV-2 infections.
慢性SARS-CoV-2感染期间适应性进化的驱动因素。
靶向泛癌RET融合
In this issue, Subbiah and colleagues report findings from ARROW, a phase 1/2 clinical trial testing pralsetinib, a tumor-agnostic inhibitor of the receptor tyrosine kinase RET, in a range of solid tumors. The cover image depicts a diverse group of patients, each with different cancers harbouring RET fusions, all treated with pralsetinib.
在本期杂志中，Subbiah及其同事报告了ARROW的发现，ARROW是一项1/2期临床试验，在一系列实体瘤中测试pralsetinib，一种与肿瘤无关的受体酪氨酸激酶RET抑制剂。封面图片描绘了一组不同的患者，每个患者都患有不同的带有RET融合的癌症，所有患者都接受了pralsetinib治疗。
1.CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia.
CRISPR-Cas9介导的BCL11A增强子的基因编辑用于小儿β0/β0输血依赖性β地中海贫血症。
2.Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.
分子分析确定了儿科实体癌的靶向治疗机会。
3.Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer.
遗传风险评分加强了对儿童癌症成年幸存者严重肥胖的风险预测。
4.Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
阿特唑单抗联合贝伐珠单抗治疗晚期肝细胞癌的临床反应和耐药性的分子相关因素。
5.Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
循环肿瘤DNA指导帕尼单抗对转移性结直肠癌的再挑战：2期CHRONOS试验。
6.Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
个性化的异源黑猩猩腺病毒和自扩增mRNA新抗原疫苗治疗晚期转移性实体瘤：1期试验中期结果。
7.Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.
瘤内溶瘤疱疹病毒G47∆治疗残余或复发胶质母细胞瘤：2期试验。
8.Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial.
1/2期ARROW试验中，pralsetinib对RET融合阳性实体瘤患者的泛癌疗效。
9.Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.
直肠癌新辅助治疗反应的基因组和转录组决定因素。
10.Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data.
使用大型真实世界临床基因组学数据对突变-治疗相互作用进行系统的泛癌症分析。
11.Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.
慢性淋巴细胞白血病里氏转化早期种子的检测。
12.Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
CETP抑制剂obicetrapib联合高强度他汀类药物的降脂作用：一项随机的2期试验。
13.Large-scale genome-wide association study of coronary artery disease in genetically diverse populations.
遗传多样性人群中冠状动脉疾病的大规模全基因组关联研究.
14.Modeling global 80-80-80 blood pressure targets and cardiovascular outcomes.
全球80-80-80血压目标和心血管疾病结果的建模。
15.City-level impact of extreme temperatures and mortality in Latin America.
拉丁美洲极端气温和死亡率的城市级影响.
16.Symptoms and risk factors for long COVID in non-hospitalized adults.
非住院成人长COVID的症状和风险因素。
17.Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
通过遗传距离分析快速评估COVID-19疫苗对SARS-CoV-2变种的症状性感染的有效性。
优化微生物群移植
Two papers in this issue from Bork et al. and Segata et al., respectively, explore factors of donor and recipient microbiomes that drive engraftment of fecal microbiota transplantation (FMT) and the effects of this dynamic process on clinical outcomes. Donor and recipient gastrointestinal tracts and their microbiomes are represented on the cover as converging pipes, demonstrating the interplay between the microbial communities after FMT, described in Bork et al.
本期的两篇论文来自Bork等人和Segata等人，他们分别探索了驱动粪便微生物群移植(FMT)植入的供体和受体微生物组的因素，以及这一动态过程对临床结果的影响。供体和受体胃肠道及其微生物组在封面上表示为会聚管道，展示了FMT后微生物群落之间的相互作用，如Bork等人所述。
1.Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein.
嵌合型Gas6融合蛋白对淀粉样蛋白的抗炎清除。
2.Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.
将分泌GDNF的人类神经祖细胞移植到ALS患者的脊髓中：一个1/2a期试验。
3.Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial.
基于智能手机的心房颤动筛查：一项务实的随机临床试验。
4.Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Atezolizumab与化疗在基于血液的高肿瘤突变负担的晚期或转移性NSCLC中的比较：BFAST队列C随机3期试验的主要分析。
5.Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.
Trastuzumab deruxtecan治疗HER2阳性乳腺癌脑转移：一项单臂2期试验。
6.Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
与难治性B细胞淋巴瘤的CAR-T疗法反应有关的独特的细胞动态。
7.Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.
灌注后的CAR TReg细胞可识别对CD19-CAR疗法有抵抗力的患者。
8.Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
肿瘤免疫环境是大B细胞淋巴瘤中抗CD19 CAR T细胞疗效的决定因素。
9.A digital mask to safeguard patient privacy.
保障患者隐私的数字面具。
10.Genetic risk factors have a substantial impact on healthy life years.
遗传风险因素对健康生活年限有很大影响。
11.Drivers and determinants of strain dynamics following fecal microbiota transplantation.
粪便微生物群移植后菌种动态的驱动因素和决定因素。
12.Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases.
粪便微生物群移植后菌种移植的可变性和不同疾病的微生物群组成的可预测性。
13.Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.
以抗体为媒介预防HIV-1感染的中和滴度生物标志物。
14.Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.
南加州SARS-CoV-2 Omicron（B.1.1.529）变体和BA.1/BA.1.1或BA.2亚变体感染的相关临床结果。
15.Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.
针对甲型流感病毒和SARS-CoV-2的关键保守病毒RNA二级结构的可编程抗病毒药物。
举证责任
In this issue, five Burden of Proof studies from the Institute for Health Metrics and Evaluation present a new method for assessing the cumulative strength of available evidence for risk factors and associated health outcomes. Together, these papers describe the methodology and demonstrate the utility of the approach with exemplars over which the burden of proof spans a range of certainty. The magnifying glass in the cover image represents the burden of proof risk function, which enables a closer view of risk factors and the evidence for associated health outcomes.
在本期杂志中，来自健康指标与评估研究所的五项举证责任研究提出了一种新方法，用于评估风险因素和相关健康结果的可用证据的累积强度。这些论文共同描述了方法，并通过范例证明了该方法的实用性，在这些范例中，举证责任涵盖了一定范围的确定性。封面图片中的放大镜代表风险函数的证明责任，可以更近距离地查看风险因素和相关健康结果的证据。
1.The Burden of Proof studies: assessing the evidence of risk.
证明研究的负担：评估风险的证据。
2.Health effects associated with smoking: a Burden of Proof study.
与吸烟有关的健康影响：证明负担的研究。
3.Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study.
收缩压升高对缺血性心脏病的影响：一项证明负担的研究。
4.Health effects associated with vegetable consumption: a Burden of Proof study.
与蔬菜消费相关的健康影响：一项证明负担的研究。
5.Health effects associated with consumption of unprocessed red meat: a Burden of Proof study.
与未加工的红肉消费相关的健康影响：证明负担的研究。
6.Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Semaglutide对成人超重或肥胖症的两年效果：STEP 5试验。
7.Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
胰高血糖素受体拮抗剂volagidemab治疗1型糖尿病：一项为期12周的随机、双盲、2期试验。
8.Microbiome-derived ethanol in nonalcoholic fatty liver disease.
非酒精性脂肪肝中微生物衍生的乙醇。
9.Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.
利用电子健康记录中的合并症签名筛查特发性肺纤维化。
10.Long-term cardiac pathology in individuals with mild initial COVID-19 illness.
轻度初始COVID-19疾病个体的长期心脏病理变化。
11.Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
抗CD19 CAR T细胞治疗难治性系统性红斑狼疮。
12.KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.
基于KIR的抑制性CARs克服了CAR-NK细胞细胞增多症介导的自相残杀和肿瘤逃脱。
13.A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
tisagenlecleucel和axicabtagene ciloleucel CAR T细胞在复发或难治性弥漫性大B细胞淋巴瘤中的真实世界比较。
14.Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
新辅助阿特唑仑治疗可切除的非小细胞肺癌：一个开放标签的单臂II期试验。
15.RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.
RNF43突变预测BRAFV600E转移性结直肠癌对抗BRAF/EGFR组合疗法的反应。
16.Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
一种强效和选择性的非共价KRASG12D抑制剂的抗肿瘤功效。
17.Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial.
Pepinemab抗体阻断SEMA4D在早期亨廷顿病中的作用：一项随机、安慰剂对照的2期试验。
18.Temporal order of clinical and biomarker changes in familial frontotemporal dementia.
家族性额颞叶痴呆症的临床和生物标志物变化的时间顺序。
19.Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals.
利用夜间呼吸信号进行帕金森病的人工智能检测和评估.
代谢个性
In this issue, Langenberg and colleagues reveal the genetic architecture that underpins individualized metabolic profiles and their relationship with clinical phenotypes. The tattoos of metabolic pathways on the cover reflect the chemical individuality of the person, with the base codes in the background representing the genetics that underlie the metabolic phenotypes.
在本期杂志中，Langenberg及其同事揭示了支持个体化代谢特征的遗传结构及其与临床表型的关系。封面上代谢途径的纹身反映了人的化学个性，背景中的基本代码代表了代谢表型背后的遗传学。
1.Proteomic signatures for identification of impaired glucose tolerance.
识别糖耐量受损的蛋白质组学特征。
2.Association of step counts over time with the risk of chronic disease in the All of Us Research Program.
我们所有人的研究计划中，步数与慢性病风险的关系。
3.Metabolomic profiles predict individual multidisease outcomes.
代谢组图谱预测个体多发病的结果。
4.Rare and common genetic determinants of metabolic individuality and their effects on human health.
代谢个体的罕见和常见遗传决定因素及其对人类健康的影响。
5.Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome.
微生物组、饮食和遗传对人类血浆代谢组的个体间差异的影响。
6.Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
饮食驱动的微生物生态学支撑着癌症免疫治疗结果与肠道微生物组之间的关联。
7.Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
循环肿瘤DNA指导下的晚期非小细胞肺癌治疗的总生存率。
8.Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
以前接受过治疗的转移性葡萄膜黑色素瘤患者对泰宾达夫的临床和分子反应：2期试验。
9.Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Cemiplimab加化疗与单纯化疗治疗非小细胞肺癌：一项随机、对照、双盲的3期试验。
10.Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
淀粉样蛋白和tau蛋白PET阳性的无认知障碍者未来认知能力下降的风险很高。
11.Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
含有二价Beta的COVID-19加强型疫苗的安全性、免疫原性和抗体持久性：2/3期试验。
12.Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
与SARS-CoV-2再感染相关的急性和急性期后遗症。
13.Long-term neurologic outcomes of COVID-19.
COVID-19的长期神经系统结果。
14.Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
回顾性地模拟增加全球疫苗共享对COVID-19大流行的影响。
15.Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
3BNC117和罗米地辛在HIV-1患者开始抗逆转录病毒治疗时的早期干预：一个1b/2a期的随机试验。
tau蛋白病的生物标志物
In this issue, Sato and colleagues tested the ability of isoform-specific tau species in cerebrospinal fluid (CSF) to distinguish different subtypes of primary tauopathies. The left and right sides of the tree portray the pathological and healthy brain, respectively, populated with leaves of tau isoforms, with the falling leaves being isoforms represented in the CSF.
在本期杂志中，Sato及其同事测试了脑脊液（CSF）中同工型特异性tau物种区分原发性tau病不同亚型的能力。树的左侧和右侧分别描绘了病态和健康的大脑，其中布满了tau亚型的叶子，落叶是CSF中代表的亚型。
1.Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction.
对智能手表检测左心室功能障碍的前瞻性评估。
2.Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.
Dapagliflozin治疗射血分数改善的心衰：DELIVER试验的特定前分析。
3.Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
恩帕里氟辛在保留射血分数的心力衰竭中的疗效：EMPEROR-Preserved的特定前分析。
4.Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality.
可穿戴设备测量的剧烈间歇性生活方式体力活动与死亡率的关系。
5.Efficacy of supermarket and web-based interventions for improving dietary quality: a randomized, controlled trial.
基于超市和网络的改善饮食质量的干预措施的有效性：一项随机对照试验。
6.Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior.
与肥胖和不良行为有关的人类血清素2C受体功能丧失变体。
7.CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
CSF tau微管结合区可识别原发性tauopathies的病理变化。
8.Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.
Aβ42/40、p-tau231和p-tau217对阿尔茨海默病试验选择和疾病监测的不同作用。
9.Global and regional estimates of orphans attributed to maternal cancer mortality in 2020.
2020年全球和区域范围内因孕产妇癌症死亡而导致的孤儿估计。
10.Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Atezolizumab联合基于蒽环类药物的化疗治疗转移性三阴性乳腺癌：随机、双盲 2b期ALICE试验。
11.Germline variants associated with toxicity to immune checkpoint blockade.
与免疫检查点阻断疗法的毒性有关的种系变异。
12.IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
IL7基因变异与黑色素瘤患者免疫检查点阻断疗法的毒性。
13.Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.
癌症免疫治疗前和治疗期间全身CD8+T细胞可视化：1/2期试验。
14.Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
早期治疗的HIV-1感染中HTI疫苗的安全性、免疫原性和对病毒反弹的影响：一项随机、安慰剂对照的1期试验。
15.Inhaled particulate accumulation with age impairs immune function and architecture in human lung lymph nodes.
随着年龄的增长，吸入的颗粒物积累损害了人类肺部淋巴结的免疫功能和结构。
16.Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial.
血管生成素样3衍生物LNA043用于骨关节炎的软骨再生：一项随机的1期试验。
17.Leukocyte telomere length in children born following blastocyst-stage embryo transfer.
囊胚期胚胎移植后出生的儿童的白细胞端粒长度。
